“The good thing about science is that it’s true whether or not you believe in it.”Neil deGrasse Tyson
Many people don’t understand science startups; they don’t really get what most of the new firms do. And many just believe that anything with ‘startup’ in it sounds cool.
However, it is not a healthy way to think about it.
Well, YES. They are cool! But for a reason!
The people working behind these companies invest a lot of their time, effort, and money to build something for the betterment of humankind. And I feel, these startups need to be recognised
In this article, I am going to list 5 such startups from the world of science that are making remarkable strides.
(The list is in alphabetical order.)
KOLs are the key to accelerating drug development. But in the past, it was a manual process and consumed a lot of time.
This is where Adnexi comes into the picture.
Founded in 2020 and based in Palo Alto, CA, Adnexi is a KOL discovery and management platform that uses technologies like artificial intelligence to scour millions of records and identify clinicians, researchers, key publications, patients advocacy leaders and clinical trials for any disease.
Not to mention, it also provides management functionality to help teams keep track of their growing relationships with these important parties.
Founded in 2019, ArsenalBio aspires to become a programmable cell therapy firm and create highly effective, accessible immune cell therapies for patients with chronic diseases, initially those with cancer.
This unique startup leverages integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm of human immune cell therapy design and treatment.
On top of that, the company is also backed by $85 million Series A financing.
This is what a document by the company reads:
“Today’s commercialized, first-generation T cell therapies are designed and manufactured to insert into T cells a single cell-targeting transgene, a chimeric antigen receptor or a new T cell receptor through viral delivery. ArsenalBio seeks to exponentially advance this process by precisely inserting, without viral vectors, significantly larger DNA payloads, designed with proprietary tools and encoding a broader set of biological “software” instructions to enable immune cells to effectively target and destroy solid organ and hematologic cancers.”
3. Korro Bio
Have you heard about RNA? RNA editing? Nope?
Let me explain. Ribonucleic acid (RNA) is a biological macromolecule that is present in all biological cells. And RNA editing is a molecular modification process. It is also considered to be an important mechanism of genetic regulation that amplifies genetic plasticity through the production of alternative protein products from a single gene.
That was about RNA.
But what’s the role of Korro Bio?
Korro Bio is one such startup that is making impressive strides in RNA editing.
Founded in 2018, its foundational platform, Oligonucleotide Promoted Editing of RNA (OPERA), is designed to fill the voids in current gene therapy and gene editing approaches, including the safety and flexibility of delivery mechanisms.
4. Passage Bio
Have you heard about Gene therapy?
It is an experimental technique that focuses on the genetic modification of cells to produce a therapeutic effect. Or simply put, it uses modified genes to treat or prevent disease.
Over the years, there were immense efforts around this field for advancement. And one of them is the adeno-associated virus (AAV) which is now proving to be one of the potent vectors.
Based in Philadelphia, PA, Passage Bio is one interesting startup that is working on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics.
Talking about its vision, the startup wants to treat the rare monogenic central nervous system disorders (CNS).
Further, the start-up has already assembled a line of product candidates.
- PBGM01 for the treatment of GM1 gangliosidosis (GM1)
- PBFT02 for the treatment of frontotemporal dementia (FTD)
- PBKR03 for the treatment of Krabbe disease
Synthekine is a development stage biotherapeutics company founded by K. Christopher Garcia, PhD in 2018. The company is focused on the engineering of novel specific, selective and potent cytokine therapies.
Cytokines are a large group of proteins, peptides or glycoproteins that are secreted by specific cells of the immune system. It also plays a central role in many key biological processes involved in the mechanism of human diseases. However, because of the pleiotropic activities, there are several complications in their development as pharmaceutical agents.
This is where California-based Synthekine comes into the picture. The startup with its deep experience in immunology and targeted protein engineering modulates cytokine agonism and generate new immunotherapies.
Not to mention, according to the company, its cytokine therapeutics are both safe and efficacious.
These are not the only startups that are pioneering the world of science and delivering solutions to some of the massive challenges.
We will cover five more science startups in our upcoming article.
So, stay tuned!